| Literature DB >> 34055121 |
Nazanin Zargar1, Elnaz Shooshtari2, Leila Pourmusavi3, Alireza Akbarzadeh Baghban4, Hengameh Ashraf1, Ardavan Parhizkar5.
Abstract
The objective of the current study was to compare the anaesthetic efficacy of supplemental intraligamentary (IL) injection of 4% articaine with that of 2% lidocaine in the mandibular first and second molars with irreversible pulpitis after an ineffective inferior alveolar nerve block injection (IANB) using the same anaesthetic in a randomised triple-blind clinical trial. Seventy-six adult patients, who were diagnosed with irreversible pulpitis in the mandibular first or second molars, were divided into 2 groups and received IANB randomly. In patients with lip numbness, anaesthesia was evaluated with the cold and electrical pulp (EPT) tests, and if the reported number on EPT was below 100, supplemental IL injection was administered using the same anaesthetic. The teeth were retested after 5 minutes. The Heft-Parker visual analogue scale was used to evaluate pain after IANB and IL injections. Statistical analysis was performed using repeated measures ANOVA, chi-square, and independent-sample and paired-sample t-tests. The results showed that there was no significant difference in the success rates of supplemental IL and IANB injections between articaine and lidocaine. Furthermore, there was no significant difference in the success rates of supplemental IL injection with lidocaine between the mandibular first and second molars. However, there was a significant difference in the success rates of supplemental IL injection with articaine between the mandibular first and second molars. Moreover, supplemental IL injections indicated no significant difference in the anaesthetic efficacy between articaine and lidocaine; nevertheless, they were more effective in the mandibular second molars, especially with articaine.Entities:
Year: 2021 PMID: 34055121 PMCID: PMC8131152 DOI: 10.1155/2021/6668738
Source DB: PubMed Journal: Pain Res Manag ISSN: 1203-6765 Impact factor: 3.037
Figure 1Consort flow diagram (IANB = inferior alveolar nerve block, IL = intraligamentary).
Success rates and confidence intervals of supplemental intraligamentary injections with lidocaine and articaine in the mandibular first and second molars.
| Total | Lidocaine | Articaine | Success ratio |
| Effect size | Power | |
|---|---|---|---|---|---|---|---|
| First molar | 59.4% (19/32) | 62.5% (10/16) | 56.3% (9/16) | 0.9 (0.5–1.6) | 1.000 | 0.064 | 0.065 |
| Second molar | 90.6% (29/32) | 81.3% (13/16) | 100% (16/16) | 1.2 (0.9–1.5) | 0.226 | 0.322 | 0.445 |
| Total | 75% (48/64) | 71.9% (23/32) | 78.1% (25/32) | 1.1 (0.8–1.4) | 0.564 | 0.072 | 0.089 |
| Success ratio (95% CI) | 0.6 (0.5–0.9) | 0.8 (0.5–1.2) | 0.6 (0.4–0.9) | ||||
|
| 0.004 | 0.433 | 0.007 | ||||
| Effect size | 0.361 | 0.209 | 0.529 | ||||
| Power | 0.823 | 0.219 | 0.849 |
The success ratio of the lidocaine group to articaine group. 1CI: confidence interval.
Summary of mean pain scores for inferior alveolar nerve block and intraligamentary injections of articaine and lidocaine in different times (mean ± SE = standard error).
| Pain groups | Tooth number | Initial pain | Pain during block injections | Pain after block injections | Pain during supplemental injections | Pain after supplemental injections | Pain during access cavity preparation | Pain in primary filing |
|---|---|---|---|---|---|---|---|---|
| Articaine (mean ± SE)95%CI | 6 | 92.81 ± 4.882.57–103.05 | 19.69 ± 4.69.86–29.51 | 47.81 ± 7.531.81–63.82 | 0.0 ± 0.0NA | 22.94 ± 5.311.60–34.27 | 40.62 ± 7.125.46–55.79 | 26.75 ± 6.013.82–39.68 |
| 7 | 97.0 ± 3.589.42–104.58 | 12.13 ± 3.64.41–19.84 | 41.06 ± 6.826.53–55.60 | 2.0 ± 1.41.01–5.01 | 9.13 ± 2.92.76–15.49 | 18.63 ± 4.010.09–27.16 | 15.13 ± 3.18.42–21.83 | |
| Total | 94.91 ± 2.988.86–100.95 | 15.91 ± 2.99.87–21.95 | 44.4 ± 5.0234.19–54.96 | 1.0 ± 0.70.47–2.47 | 16.03 ± 3.29.41–22.65 | 29.63 ± 4.420.50–38.75 | 20.94 ± 3.513.76–28.12 | |
|
| ||||||||
| Lidocaine (mean ± SE) | 6 | 101 ± 4.990.41–111.71 | 14.63 ± 3.37.55–21.70 | 49.81 ± 7.633.56–66.06 | 0.63 ± 0.40.29–1.54 | 26.81 ± 5.115.93–37.69 | 45.06 ± 5.732.83–57.30 | 28.75 ± 5.317.42–40.08 |
| 7 | 88.63 ± 4.179.79–97.46 | 13.69 ± 3.95.31–22.07 | 35.63 ± 6.222.37–48.88 | 2.81 ± 1.40.26–5.88 | 13.44 ± 3.75.43–21.44 | 25.81 ± 5.613.70–37.93 | 22.75 ± 5.111.78–33.72 | |
| Total | 94.84 ± 3.387.95–101.74 | 14.16 ± 2.58.99–19.32 | 42.72 ± 5.032.51–52.92 | 1.72 ± 0.70.16–3.28 | 20.12 ± 3.313.31–26.94 | 35.44 ± 4.326.60–44.27 | 25.75 ± 3.618.25–33.25 | |
|
| ||||||||
| Total (mean ± SE) | 6 | 96.94 ± 3.489.82–104.05 | 17.16 ± 2.811.38–22.93 | 48.81 ± 5.238.07–59.55 | 0.31 ± 0.20.13–0.76 | 24.88 ± 3.617.45–32.30 | 42.84 ± 4.533.64–52.05 | 27.75 ± 3.919.65–35.85 |
| 7 | 92.81 ± 2.787.12–98.5 | 12.91 ± 2.67.54–18.28 | 38.34 ± 4.529.03–47.65 | 2.41 ± 0.90.38–4.44 | 11.28 ± 2.36.40–16.16 | 22.22 ± 3.415.12–29.32 | 18.94 ± 3.012.73–25.15 | |
| Total | 94.88 ± 2.290.42–99.33 | 15.03 ± 0.911.16–18.9 | 43.58 ± 3.536.55–50.61 | 1.36 ± 0.50.32–2.40 | 18.08 ± 2.313.43–22.72 | 32.53 ± 3.126.31–38.75 | 23.34 ± 2.518.26–28.43 | |
Not applicable.
Mean pulse rates before and after inferior alveolar nerve block and intraligamentary injections with articaine and lidocaine.
| Variables | Technique | Mean ± SE | 95% CI |
|
|---|---|---|---|---|
| Initial pulse rate | Articaine | 81.78 ± 1.503 | 78.72–84.85 | 0.860 |
| Lidocaine | 82.16 ± 79.11 | 79.11–85.20 | ||
|
| ||||
| Pulse rate after IANB | Articaine | 86.81 ± 1.500 | 83.75–89.87 | 0.628 |
| Lidocaine | 85.72 ± 1.671 | 82.31–89.13 | ||
|
| ||||
| Pulse rate after IL injection | Articaine | 92.53 ± 1.503 | 89.47–95.60 | 0.463 |
| Lidocaine | 90.84–1.720 | 87.33–94.35 | ||
Figure 2Summary of results.